[
{
	"page":"ENAS5410_1.0.0.0",
	"text":"1.0.0.0 Authors and legal information GUIDELINES COMMITTEE Chair: George Pentheroudakis; Co-‍Chair: Cristiana Sessa; Steering Committee Members: Dirk Arnold, Christian Buske, Fatima Cardoso, Paolo Casali, Andrés Cervantes, Elisabeth de Vries, Alan Horwich, Solange Peters, Rolf Stahel; Subject Editors: Jean-Yves Blay, Nicoletta Colombo, Karin Jordan, Ulrich Keilholz, Marco Ladetto, Lisa Licitra, Matthias Preusser, Carla Ripamonti, Elzbieta Senkus-Konefka; Deputy Subject Editors: Alfredo Berruti, Silke Gillessen, Mats Jerkeman, Jean-Pascal Machiels, Erika Martinelli, Ulrich Mey, Olivier Michielin, Martin Reck; Staff: Keith McGregor, Claire Bramley, Jennifer Lamarre, Sarah Escuin, Jean-Yves Douillard, Svetlana Jezdic. ESMO CLINICAL PRACTICE GUIDELINES Central venous access in oncology: ESMO Clinical Practice Guidelines Sousa B, Furlanetto J, Hutka M, Gouveia P, Wuerstlein R, Mariz JM, Pinto D and Cardoso F, on behalf of the ESMO Guidelines Committee Ann Oncol 2015;26 (Suppl 5):v152–68 http:/‍/‍annonc.oxfordjournals.org/‍content/‍‍26/‍suppl_5/v152.full.pdf+html Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-‍‍up Peterson DE, Boers-‍‍Doets CB, Bensadoun RJ and Herrstedt J, on behalf of the ESMO Guidelines Committee Ann Oncol 2015;26 (Suppl 5):v139–51 http:/‍/‍annonc.oxfordjournals.org/‍content/‍‍26/‍suppl_5/v139.full.pdf+html Prevention of chemotherapy-‍‍ and radiotherapy-‍‍induced nausea and vomiting and of nausea and vomiting in advanced cancer patients: 2016 MASCC and ESMO guideline update Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-‍‍Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D and van der Wetering M, on behalf of the participants of the MASCC-‍‍ESMO Consensus Conference Ann Oncol 2016; 27 (Suppl 5): v119–33 http:/‍/‍annonc.oxfordjournals.org/‍content/‍‍27/‍suppl_5/v119.full.pdf+html Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines Mandalà M, Falanga A and Roila F, on behalf of the ESMO Guidelines Working Group Ann Oncol 2011;22(Suppl 6):vi85–92 http:/‍/‍annonc.oxfordjournals.org/‍content/‍‍22/‍suppl_6/vi85.full.pdf+html Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C and Roila F, on behalf of the ESMO Guidelines Working Group Ann Oncol 2012;23(Suppl 7):vii155–66 http:/‍/‍annonc.oxfordjournals.org/‍content/‍‍23/‍suppl_7/vii155.full.pdf+html Management of chemotherapy extravasation: ESMO-‍EONS Clinical Practice Guidelines Pérez Fidalgo JA, García Fabregat L, Cervantes A, Marguiles A, Vidall C and Roila F, on behalf of the ESMO Guidelines Working Group Ann Oncol 2012;23(Suppl 7):vii167–73 http:/‍/‍annonc.oxfordjournals.org/‍content/‍‍23/‍suppl_7/vii167.full.pdf+html Management of febrile neutropaenia: ESMO Clinical Practice Guidelines Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M and Herrstedt J, on behalf of the ESMO Guidelines Committee Ann Oncol 2016; 27 (Suppl 5): v111–8 http:/‍/‍annonc.oxfordjournals.org/‍content/‍‍27/‍suppl_5/v111.full.pdf+html Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines Roselló S, Blasco I, García Fabregat L, Cervantes A and Jordan K, on behalf of the ESMO Guidelines Committee Ann Oncol 2017;28(Suppl 4):iv100–18 https://​academic.oup.com/​annonc/​article-pdf/​28/​suppl_4/​iv100/18528215/​mdx216.pdf Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J and Jordan K, on behalf of the ESMO Guidelines Committee Ann Oncol 2017;28(Suppl 4):iv119–42 https://​academic.oup.com/​annonc/​article-pdf/​28/​suppl_4/​iv119/​3958159/​mdx225.pdf ESMO POCKET GUIDELINES PROVIDE YOU WITH A CONCISE SUMMARY OF THE FUNDAMENTAL RECOMMENDATIONS MADE IN THE PARENT GUIDELINES IN AN EASILY ACCESSIBLE FORMAT. This quick reference booklet provides you with the most important content of the full ESMO Clinical Practice Guidelines (CPGs) and consensus statements on various aspects of supportive care for your patients. Key content includes central venous access in oncology; prevention of chemotherapy-‍‍ and radiotherapy induced nausea and vomiting; and management of febrile neutropenia, mucositis, venous thromboembolism, extravasation associated with the administration of chemotherapeutic agents and of the cardiotoxic effects of chemotherapy and radiotherapy. The ESMO CPG and consensus statements covered in this booklet are intended to provide you with a set of recommendations for the best standards of supportive care, using evidence-‍‍based medicine. Implementation of ESMO CPG and consensus statements facilitates knowledge uptake and helps you to deliver an appropriate quality of focused care to your patients. The approval and licensed indication of drugs mentioned in this pocket guideline may vary in different countries. Please consult your local prescribing information. This booklet can be used as a quick reference guide to access key content on supportive care in cancer. Please visit http://www.esmo.org or http://oncologypro.esmo.org to view the full guidelines."
},
{
	"page":"ENAS5410_2.1.0.0",
	"text":"2.0.0.0 Incidence and epidemiology 2.1.0.0 Overview Immune-‍related adverse events (irAEs) from the anti-‍cytotoxic T lymphocyteassociated protein 4 (CTLA4) monoclonal antibody (MoAb) ipilimumab (3 mg/kg) occur in 60-85% of patients, mostly grade 1 and 2, with 10–27% patients developing grade 3–4 toxicities Toxicities are dose-‍dependent and the onset varies, as shown in the figures below/‍on the next page, but usually starts within the first 12 weeks of initiation of treatment High-‍grade toxicities from anti-‍programmed death 1 (PD-1) antibodies, nivolumab or pembrolizumab, are less common than with ipilimumab Treatment-‍related adverse events (AEs) ≥ grade 3 occur in 55% of patients receiving combined anti-‍CTLA4 and anti-‍PD-‍1/‍programmed death ligand 1 (PD-L1) and the onset for either nivolumab monotherapy or combined immunotherapy varies, as shown in the figure here"
},
{
	"page":"ENAS5410_2.2.0.0",
	"text":"2.2.0.0 TIMING OF OCCU. OF irAEs FOLLOW. IPILIMUMAB Tx. Weber JS et al. J Clin Oncol 2012;30:2691–2697. Reprinted with permission. ©2012 American Society of Clinical Oncology. All rights reserved."
},
{
	"page":"ENAS5410_2.3.0.0",
	"text":"2.3.0.0 Time to onset of gr. 3–4 Tx.-related select AEs Larkin J et al. Presented at ECC 2015;Abs330. Reprinted with permission."
},
{
	"page":"ENAS5410_2.4.0.0",
	"text":"2.4.0.0 General aspects of irAEs irAEs generally occur within weeks to 3 months after initiation of immune checkpoint blockers, although they can be reported up to one year after discontinuation of treatment The role of tissue biopsy in the diagnosis of immune-therapy related toxicity is not established but may be useful for higher grade (3–4) toxicities of the skin, gastrointestinal (GI) tract, liver, kidney and lung where there is diagnostic doubt about the aetiology of the complication and management would be altered by the outcome of the biopsy procedure The reporting pathologist should be informed of the reasons for the biopsy"
},
{
	"page":"ENAS5410_2.5.0.0",
	"text":"2.5.0.0 Patient selection and baseline assessments Prior to starting treatment, a patient’s susceptibility to irAE development should be assessed The work-‍up should include patient (and family) history, general physical condition, autoimmune diseases, baseline laboratory tests and radiological scans Triiodothyronine (T3) testing is required only in case of suspicion of abnormal thyroid gland function, but with normal free thyroxine (FT4) At baseline, complete blood counts, liver functions tests, renal function, electrolytes, glucose, lactate dehydrogenase (LDH), erythrocyte sedimentation rate (ESR), pancreatic tests, hormonal axis tests (thyroid function test [TFT] for anti-‍PD-‍1/PD-L1, and all [TFT, adrenal function tests and gonadotropin hormonal tests] for anti-‍CTLA4 and combination immunotherapy) are recommended Baseline computed tomography (CT) scans (chest and abdominal/‍pelvis) and brain magnetic resonance imaging (MRI) are recommended At follow-‍up, CT scans should be performed every 12 weeks, with brain MRI indicated only when it is abnormal at baseline Follow-‍up laboratory tests (similar to baseline) should be performed every 3 weeks prior to every infusion during the first 12 weeks for anti-‍CTLA4 treatment, then at every follow-‍up visit (preferably every 6 weeks) for 3 months after the last anti-‍CTLA4 treatment, and every 3 months thereafter For 2-‍weekly anti-‍PD-‍1/PD-L1 treatment, follow-‍up laboratory tests should be performed every 2 weeks during the first 12 weeks and, if normal, every subsequent 4 weeks, and at every follow-‍up visit until 3 months after last anti- PD-1/PD-L1 infusion, then every 3 months thereafter For 3-‍weekly anti-‍PD-‍1/PD-L1 treatment, laboratory tests should be performed prior to every infusion and at every follow-‍up visit, at least until 3 months after the last infusion; thereafter every 3 months For the combination of anti-‍CTLA4 + anti-‍PD-‍1/PD-L1, laboratory tests should be performed at every infusion (also during anti-‍PD-‍1/PD-L1 maintenance) and every 6 weeks until 3 months after the last infusion, thereafter every 3 months Patients who have a current, or a history of, autoimmune disease are at risk for worsening of their autoimmune disease while on immune checkpoint inhibitor (ICPi) treatment Patients with previous ipilimumab-‍related irAEs are at risk of developing irAEs following anti-‍PD-‍1 treatment and vice versa; the time between last dose of first drug and initiation of the second drug may be an important factor Patients should be informed of the potential AEs of immunotherapy before treatment initiation and should report directly to the treating physician or team Once irAEs have developed, prompt work-‍up and action to prevent aggravation of side effects is required In many cases, especially the most severe, immunotherapy should be discontinued and immunosuppressive or immune-modulating drugs are required Long-‍term (> 6 weeks) treatment with immunosuppressive drugs or use of infliximab increases the chance of opportunistic infections and Pneumocystis prophylaxis should be considered The clinical outcome of patients on ICPi treatment is not affected by the use of immunosuppressive agents for the management of immune-‍related toxicities"
},
{
	"page":"ENAS5410_3.1.1.0",
	"text":"3.0.0.0 Immune-‍related toxicities 3.1.0.0 Immune-‍related skin toxicity 3.1.1.0 Overview Skin AEs are among the most frequent side effects in patients treated with anti- CTLA4 and PD-1 MoAbs and usually develop within the first few weeks of treatment Serious skin AEs are rare and do not usually require dose reductions or treatment discontinuation The most frequent skin AEs are rash, pruritus and vitiligo, the latter being seen mainly in patients treated for melanoma, where it is associated with good clinical responses to anti-‍PD-‍1 antibodies Less common skin AEs include alopecia areata, stomatitis, xerosis cutis, photosensitivity, exacerbation of psoriasis, psoriasiform or lichenoid skin reactions Skin reactions can be classified into four categories: Inflammatory skin disorders, reflecting acute, subacute or chronic inflammation and associated with variable epidermal changes, including psoriasiform or lichenoid reactions Immunobullous skin lesions, similar to dermatitis herpetiformis or bullous pemphigoid Keratinocyte alteration (Grover’s disease/acantholytic dyskeratosis) Immune-reaction mediated by alteration of melanocytes (regression of nevi, prurigo nodularis, tumoural melanosis and vitiligo)"
},
{
	"page":"ENAS5410_3.1.2.0",
	"text":"3.1.2.0 Diagnosis and pathology Any other aetiology of the skin problem, such as an infection, an effect of another drug or a skin condition linked to another systemic disease, should be ruled out The severity of the reaction should be evaluated by a careful and thorough physical examination of the skin, including the mucosal areas, and patient’s general health status (fever, enlarged lymph nodes, etc) A biological assessment, including blood cell count and liver and kidney tests, may be required to rule out dermatological emergencies, such as drug rash with eosinophilia and systemic symptoms (DRESS), acute febrile neutrophilic dermatosis (Sweet syndrome), Stevens Johnson syndrome or toxic epidermal necrolysis (TEN) ICPi treatment should be permanently discontinued, the patient hospitalised and symptomatic treatment should be initiated immediately by a dermatologist Severity of maculopapular rash should be classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0"
},
{
	"page":"ENAS5410_3.1.3.1",
	"text":"3.1.3.0 Management of rash 3.1.3.1 Overview The management of rash is shown in the figure here For grade 1 skin AEs such as rash and/‍or pruritus, ICPi treatment can be continued and symptomatic treatment with topical emollients, oral antihistamines and/‍or mild strength topical corticosteroids is recommended For grade 2 skin AEs, ICPi treatment can be continued but if the reaction has not resolved within a week, treatment should be interrupted until the skin AE has reverted to ≤ grade 1 Symptomatic treatment with topical emollients, oral antihistamines and medium-‍to-‍high-‍strength topical steroids is recommended Grade 3 skin reactions require immediate ICPi interruption until reactions are ≤ grade 1 and treatment with topical emollients, oral antihistamines and highstrength topical steroids Systemic corticosteroids 0.5 to 1 mg/kg can be considered, depending on the severity of the symptoms Grade 4 skin toxicity is rare; ICPi treatment should be interrupted and patients should be admitted immediately and placed under supervision of a dermatologist Treatment consists of intravenous (IV) (methyl)prednisolone 1–2 mg/kg with tapering when toxicity resolves"
},
{
	"page":"ENAS5410_3.1.3.2",
	"text":"3.1.3.2 Schematic of body surface area"
},
{
	"page":"ENAS5410_3.2.1.1",
	"text":"3.2.0.0 Immune-‍related endocrinopathies 3.2.1.0 Thyroid gland disorders 3.2.1.1 Overview Thyroid dysfunction rates range from 1–5% with 3 mg/kg ipilimumab to 5-10% with anti-‍PD-‍1 or anti-‍PD-‍L1 therapy, reaching 20% with combination immunotherapy (ipilimumab 3 mg/kg plus nivolumab 1 mg/kg) Events are rarely higher than grade 2 In most cases, thyroid dysfunction is found by routine blood tests (thyroid-‍stimulating hormone [TSH] and FT4), which should be performed before every infusion or at least once a month (in the case of 2-‍weekly infusions) The management of thyroid gland disorders is shown in the figure on the next page Substitution with thyroid hormone should be considered in asymptomatic patients with fatigue or other complaints that could be attributed to hypothyroidism In symptomatic patients, especially in the case of hyperthyroidism, treatment with beta-‍blockers should be initiated (propranolol or atenolol) Rarely, carbimazole or steroids are required and ICPi treatment should be interrupted until recovery from symptoms has occurred Hormone replacement therapy (HRT) is required in most patients and is usually long lasting"
},
{
	"page":"ENAS5410_3.2.2.1",
	"text":"3.2.2.0 Hypophysitis 3.2.2.1 Overview Hypophysitis, an inflammation of the anterior lobe of the pituitary gland, is reported with ipilimumab 3 mg/kg, ipilimumab 10 mg/kg and the combination of ipilimumab and nivolumab in 1%, 16 and 8%, respectively, but is rare with single-‍agent anti-‍PD-‍1 and anti-‍PD-‍L1 antibodies Patients may present with different complaints and headache and visual disturbances require immediate evaluation and differentiation between hypophysitis and other conditions such as cerebral metastasis, leptomeningeal disease and cerebrovascular disease On brain MRI, a swollen or enlarged pituitary gland may be visible Simultaneous low blood levels of TSH, adrenocorticotropic hormone (ACTH) and/‍or follicle-stimulating hormone/luteinising hormone (FSH/‍LH) indicate hypophysitis Patients can present with hypothyroidism and/‍or hypocortisolism and with complaints relating to low testosterone levels The management of hypophysitis is shown in the figure here Following a confirmed diagnosis, ICPi treatment should be interrupted in any grade 2 or higher reaction and HRT should be initiated immediately In case of headaches and other neurological problems, high-‍dose steroids should be given In most cases, ICPi can be continued Long-‍term HRT is required in most patients"
},
{
	"page":"ENAS5410_3.2.3.0",
	"text":"3.2.3.0 Type 1 diabetes mellitus Blood glucose levels should be regularly monitored in patients treated with ICPi in order to detect the emergence of de novo diabetes mellitus (DM), which occurs at a low frequency (< 1%) and is more common with PD-1 and PD-L1 blockade (or combination immunotherapy) than with ipilimumab Patients with Type 2 DM may develop ketoacidosis, which should be treated according to standard local guidelines The efficacy of high-‍dose steroids to prevent total loss of pancreatic beta cells is unclear, but steroids will negatively influence diabetes control C-‍peptide and antibodies against glutamic acid decarboxylase (GAD) and islet cells should be measured to distinguish between Type 1 and Type 2 DM Recommencement of ICPi treatment can be considered once the patient has been regulated with insulin substitution"
},
{
	"page":"ENAS5410_3.3.1.0",
	"text":"3.3.0.0 Immune-‍related hepatotoxicity 3.3.1.0 Overview Hepatitis occurs in 5–10% of patients receiving single-‍agent ipilimumab, nivolumab and pembrolizumab and in 25–30% of those receiving combined treatment (ipilimumab 3 mg/kg and nivolumab 1 mg/kg) All patients should be assessed for signs and symptoms of hepatitis with measurement of serum transaminases and bilirubin prior to every treatment cycle If hepatitis develops, disease-‍related causes, concomitant drug administration (including alcohol) and infectious causes, particularly viral hepatitis, should be ruled out Initiation of therapy should not be delayed while awaiting serological results if there is no other apparent cause Liver biopsy may be help in the differential diagnosis of more severe hepatitic reactions, such as lobular hepatitis, which is indistinguishable from autoimmune hepatitis Additional sinusoidal histiocytosis and central vein endothelitis may help identify ipilimumab-‍associated inflammation Rare cases show portal tract inflammation and cholangitis or changes indistinguishable from non-‍alcoholic steatohepatitis (NASH)"
},
{
	"page":"ENAS5410_3.3.2.1",
	"text":"3.3.2.0 Management 3.3.2.1 Overview Management options are shown in the figure here For moderate (grade 2) transaminase or total bilirubin elevation, ICPi therapy should be withheld and transaminases and bilirubin measured twice weekly Grade 2 elevation persisting for more than 1–2 weeks should be treated with corticosteroids (1 mg/‍kg/‍day [methyl]prednisolone or equivalent) and, if symptoms improve, ICPi therapy may be resumed after corticosteroid tapering If symptoms do not improve, or worsen, the corticosteroid dose should be increased to 2 mg/‍kg/‍day (methyl)prednisolone or equivalent and ICPi therapy should be permanently discontinued For grade 3 or 4 transaminase or total bilirubin elevation, corticosteroids should be started at 1–2 mg/‍kg/‍day (methyl)prednisolone or equivalent and ICPi therapy should be permanently discontinued If there is no response to corticosteroids within 2–3 days, mycophenolate mofetil (MMF) should be added (1,000 mg twice daily [bid]) Consultation with a hepatologist and consideration of liver biopsy is recommended in steroid-‍ and mycophenolate-refractory cases Third-‍line immunosuppressive therapy is not well defined but options include anti-‍thymocyte globulin (ATG) and tacrolimus Infliximab is not recommended for the treatment of immune-‍related hepatitis Hepatitis usually resolves within 4–6 weeks with appropriate treatment If hepatitis does not resolve, other contributory causes should be reconsidered and the initial diagnostic work-‍up repeated as necessary"
},
{
	"page":"ENAS5410_3.4.1.1",
	"text":"3.4.0.0 Gastrointestinal toxicity 3.4.1.0 GI toxicity of anti-‍CTLA4 antibodies 3.4.1.1 Overview GI toxicity is one of the most frequent irAEs associated with anti-‍CTLA4, with diarrhoea being reported in one-‍third of patients and colitis in 8–22% and the onset of GI symptoms may occur at any time during 1 and 10 infusions The most common presenting symptoms of anti-‍CTLA4-‍induced enterocolitis after diarrhoea are abdominal pain, hematochezia, weight loss, fever and vomiting, mouth ulcers, anal lesions and extra-‍intestinal manifestations (such as arthralgia, endocrine disorders, skin disorders, hepatitis, nephritis, pericarditis, pancreatitis) The main biological abnormalities are anaemia, increased serum C-‍reactive protein (CRP) and low serum albumin levels, and some patients have antibodies against the enteric flora and neutrophils Stools bacterial enteropathogens and Clostridium difficile toxin in the event of significant diarrhoea and involvement of GI metastases should be eliminated Erythema/loss of vascular pattern, erosions and ulcerations in the sigmoid colon and rectum are common and a flexible sigmoidoscopy is generally sufficient to confirm the diagnosis Endoscopic lesions of the colon are often extensive and may extend proximally to the sigmoid colon Histologically, the reaction is an acute colitis, with neutrophil and eosinophil infiltration, and is either diffuse or focal with patchy crypt abscesses, sometimes with features characteristic of chronic inflammatory bowel disease, such as granulomas, basal plasmacytosis and crypt abnormalities Upper GI symptoms (dysphagia and epigastric pain) and endoscopic lesions (oesophageal ulcerations, gastritis, duodenitis), and chronic, mild, patchy inflammation of the stomach and duodenum may be present Severity should be assessed according to CTCAE, version 4 Severe diarrhoea refers to grade 3 or 4 diarrhoea and grade 1 or 2 diarrhoea with dehydration, fever, tachycardia or haematochezia Flexible sigmoidoscopy or colonoscopy is recommended in patients with severe diarrhoea or persistent grade 2 diarrhoea"
},
{
	"page":"ENAS5410_3.4.1.2",
	"text":"3.4.1.2 Management overview Management options are shown in the figure here Oral budesonide does not prevent ipilimumab-‍induced enterocolitis For non-‍severe diarrhoea, antidiarrhoeals, fluid and electrolyte supplementation, if required, and continuation of anti-‍CTLA4 therapy is recommended For persistent grade 2 diarrhoea or severe diarrhoea (grade 3/4 diarrhoea, or grade 1/2 diarrhoea with alarm symptoms) anti-‍CTLA4 therapy discontinuation and initiation of systemic corticosteroids (1 to 2 mg/kg IV daily) is recommended Patients responding to IV corticosteroids within 3–5 days should be switched to the oral form and treatment should be tapered over 8–12 weeks; non-‍responders should be switched to infliximab (unless contraindicated) A single dose of infliximab (5 mg/kg) is generally sufficient, although some patients may need a second dose 2 weeks after the first Vedolizumab is a potentially effective alternative to infliximab, but additional studies are required to evaluate its safety and efficacy The role of cytomegalovirus (CMV) reactivation requires further investigation Patients developing a colonic perforation, with or without intra-‍abdominal abscess, should undergo emergency colectomy Subtotal colectomy with ileostomy and sigmoidostomy is recommended due to the extensive nature of lesions and severe postoperative inflammation No routine biomarker has been found to predict ipilimumab-‍related colitis, although baseline microbiota composition may be useful"
},
{
	"page":"ENAS5410_3.4.1.4",
	"text":"3.4.1.4 Follow-‍up and long-‍term implications The relationship between ipilimumab-‍induced enterocolitis and tumour regression or overall survival (OS) is unclear Treatment with corticosteroids or infliximab does not affect response and OS of patients treated with ipilimumab More studies are needed to determine if endoscopic or histological colon inflammation observed post-enterocolitis in some patients evolves into chronic inflammatory bowel disease Reintroduction of anti-‍CTLA4 in patients who have previously experienced enterocolitis is associated with a high risk of relapse and should be discussed on an individual basis A severe AE with an anti-‍CTLA4 MoAb does not predict toxicity with an anti-‍PD-‍1 MoAb, and vice versa"
},
{
	"page":"ENAS5410_3.4.2.0",
	"text":"3.4.2.0 GI toxicity of anti-‍PD-‍1 antibodies There are very few data available on anti-‍PD-‍1 MoAb-‍associated GI irAEs Common symptoms include diarrhoea, nausea/vomiting and abdominal pain, with a median time to symptom onset of 3 months Endoscopic findings range from normal mucosa through mild erythema to severe inflammation Histological findings include lamina propria expansion, villus blunting, intra-‍epithelial neutrophils and increased crypt/‍gland apoptosis Recent studies have identified four different patterns of GI irAEs, including acute colitis similar to that induced by anti-‍CTLA4 antibodies, microscopic colitis, upper GI involvement and pseudo-‍obstruction"
},
{
	"page":"ENAS5410_3.4.3.0",
	"text":"3.4.3.0 Combined anti-‍CTLA4 & anti-‍PD-‍1 antibodies Diarrhoea and colitis occur earlier and more frequently with combined anti-‍CTLA4 and anti-‍PD-‍1 agents than with either agent alone Pancreatitis and small bowel enteritis, which may be visible on CT scan, require ICPi treatment discontinuation and initiation of immunosuppression There is a need for a more detailed description of GI irAEs associated with combined anti-‍CTLA4 and anti-‍PD-‍1 MoAbs"
},
{
	"page":"ENAS5410_3.5.1.0",
	"text":"3.5.0.0 Immune-‍related pneumonitis 3.5.1.0 Overview Pneumonitis is reported in 2-4% of patients receiving anti-‍PD-‍1/PD-L1 MoAbs, with no difference in the incidence between the anti-‍PD-‍1 and anti-‍PD-‍L1 agents Pneumonitis tends to occur later than other irAEs, commonly some months after treatment was initiated Acute interstitial pneumonitis/diffuse alveolar damage syndrome (DADS) is the most acute, life-‍threatening event, but organising inflammatory pneumonia and sarcoidosis-‍like pulmonary granulomatosis have also been reported Any new respiratory symptom should prompt investigation to formally exclude lung toxicity and all patients presenting with pulmonary symptoms should be assessed by CT Radiological features include ground glass opacities, a cryptogenic organising pneumonia-‍like appearance and interstitial pneumonia pattern, as well as characteristics of hypersensitivity pneumonitis Lung biopsy is generally not required for patient management, unless there is doubt as to the aetiology of pulmonary infiltrates If not apparent clinically, identification of DADS may be useful in terms of treatment and prognostication Other patterns of lung reaction attributed to immunotherapy are not specific and reflect a range of chronic inflammatory processes A video-‍assisted thoracoscopic surgery (VATS) biopsy is more likely to secure a specific diagnosis than a transbronchial lung biopsy; the decision to perform a biopsy and the choice of technique will depend on the location and distribution of the disease on imaging, the surgical team and any specific risks to the patient The pathologist should be informed about the background to, and reason for, the diagnostic procedure Alternatively, a bronchoscopy with bronchoalveolar lavage (BAL) will support the identification of infections and is recommended in any symptomatic pneumonia"
},
{
	"page":"ENAS5410_3.5.2.1",
	"text":"3.5.2.0 Management 3.5.2.1 Overview Management options are shown in the figure here Where immune-‍related pneumonitis is documented or suspected, immunosuppressive treatment should be started immediately Infection should be ruled out by bronchoscopy, especially in the case of grade ≥ 2 pneumonitis, but if this is not possible parallel administration of oral or IV broad-‍spectrum antibiotics and immunosuppressive treatment for grade ≥ 3 pneumonitis is recommended For grade 1–2 pneumonitis, treatment with oral prednisone 1 mg/kg daily or equivalent is recommended and with clinical assessments every 2–3 days initially, including radiological assessments for grade 2 pneumonitis Following recovery, steroids should be tapered over 4–6 weeks and ICPi reintroduction delayed until the daily steroid dose is ≤ 10 mg of oral prednisone In grade 3–4 moderate-to-severe cases, hospitalisation, treatment with high-dose IV (methyl)prednisolone 2–4 mg/‍kg/‍day or equivalent and permanent discontinuation of ICPi treatment is recommended If there is no improvement in the patient’s condition or in imaging after 2 days, additional immunosuppressive strategies, such as infliximab, MMF or cyclophosphamide, are recommended Steroids should be tapered slowly, over 6 weeks or more, as there is a possibility of pneumonitis recurrence following rechallenge"
},
{
	"page":"ENAS5410_3.6.1.1",
	"text":"3.6.0.0 Rare immune-‍related toxicities 3.6.1.0 Neurological toxicity 3.6.1.1 Overview The incidence of neuro-‍related AEs is reported as 1%, but recent trials have reported higher incidences, with around 3.8% with anti-‍CTLA4 agents, 6.1% with anti-‍PD-‍1 agents and 12% with combination anti-‍CTLA4/anti-‍PD-‍1 treatment Variable time of onset ranges from 6 to 13 weeks Neurological events include polyneuropathy, facial nerve paresis, demyelination, myasthenia gravis, Guillain-‍Barré syndrome (GBS), posterior reversible leukoencephalopathy, transverse myelitis, enteric neuropathy, encephalitis and aseptic meningitis Progression of the underlying cancer, seizure activity, infection and metabolic derangement should be ruled out Nerve conduction studies and lumbar puncture may assist in diagnosis and early consultation with a neurologist is advised For all but mild (grade 1) neurological symptoms, ICPi therapy should be withheld until the nature of the AE is defined Prednisolone 0.5–1 mg/kg should be considered for moderate symptoms High-‍dose oral prednisolone (1–2 mg/kg) or IV equivalent is recommended for significant neurological toxicity Plasmapheresis or IV immunoglobulin (Ig) may be required for the treatment of myasthenia and GBS Management options are shown in the figures on the next page"
},
{
	"page":"ENAS5410_3.6.2.0",
	"text":"3.6.2.0 Cardiac toxicity The incidence of cardiac side effects, including myocarditis, pericarditis, arrhythmias, cardiomyopathy and impaired ventricular function, is generally low but has been reported after treatment with ipilimumab, pembrolizumab and nivolumab The incidence is higher with the combination of ipilimumab and nivolumab compared with nivolumab alone Early consultation with a cardiologist is recommended High-‍dose corticosteroids (1–2 mg/kg) should be instituted rapidly if ICPi- induced cardiac side effects are suspected Escalation to other immunosuppressive drugs, such as infliximab, MMF and ATG, is recommended if symptoms do not respond promptly to steroids"
},
{
	"page":"ENAS5410_3.6.3.1",
	"text":"3.6.3.0 Rheumatological toxicity 3.6.3.1 Overview Mild or moderate myalgias and arthralgias occur in 2–12% of patients and are more common with anti-‍PD-‍1 agents Vasculitis, polymyositis, myositis and temporal arteritis have also been described For mild or moderate symptoms, analgesia with paracetamol and/‍or non-steroidal anti-‍inflammatory drugs (NSAIDs) is recommended, as shown in the figure here Moderate symptoms may respond to prednisolone at a dose of 10–20 mg per day or equivalent For severe symptoms, consultation with a rheumatologist and consideration of the use of high dose corticosteroids and tumour necrosis factor alpha-‍blocking agents is recommended"
},
{
	"page":"ENAS5410_3.6.4.1",
	"text":"3.6.4.0 Renal toxicity 3.6.4.1 Overview Renal dysfunction is rare with ipilimumab and with anti-‍PD-‍1 monotherapy (< 1%) but is more common with ipilimumab plus nivolumab (4.9%) and sequential ipilimumab/nivolumab treatment (5.1%) Serum sodium, potassium, creatinine and urea prior to every ICPi infusion is recommended Initial management involves stopping nephrotoxic drugs, ruling out infection and urinary tract obstruction and correcting hypovolaemia For significant renal dysfunction, ICPi treatment should be withheld and consideration given to the use of systemic (methyl)prednisolone 0.5–2 mg or equivalent In the event of severe renal dysfunction, a nephrologist should be consulted Renal biopsy may be used to clarify a difficult differential diagnosis Acute tubulo-‍interstitial nephritis with lymphocytic infiltration is a frequent biopsy finding and management options are shown in the figure on the next page Granulomatous changes are seen in about a quarter of patients"
},
{
	"page":"ENAS5410_3.6.5.0",
	"text":"3.6.5.0 Ocular toxicities irAEs of the eye are rare (< 1%) and comprise ocular inflammation (peripheral ulcerative keratitis, uveitis and Vogt-‍Koyanagi-‍Harada syndrome), orbital inflammation (thyroid-‍associated orbitopathy), idiopathic orbital inflammation (scleritis, myositis, neuritis, dacryoadenitis) and retinal and choroidal disease (choroidal neovascularisation and melanoma-‍associated retinopathy) Treatment depends on severity, with topical corticosteroids for episcleritis and anterior uveitis and systemic corticosteroids for severe ocular inflammation and orbital inflammation Intravitreal anti-‍vascular endothelial growth factor (VEGF) treatment is indicated for choroidal neovascularisation"
},
{
	"page":"ENAS5410_3.6.6.0",
	"text":"3.6.6.0 Haematological toxicities Immune-‍related haematological AEs are rare and include lethal aplastic anaemia, autoimmune haemolytic anaemia and immune thrombocytopaenic purpura The optimal treatment is unknown and initiation of high-‍dose corticosteroids and other immunosuppressive drugs should be performed in close collaboration with a haematologist"
},
{
	"page":"ENAS5410_3.6.7.0",
	"text":"3.6.7.0 Allograft rejection Limited literature indicates that single-‍agent ipilimumab may be administered without causing rejection of cardiac, renal and liver allografts, but there is a risk of acute allograft rejection after anti-‍PD-‍1 therapy This should be discussed with patients who might benefit from anti-‍PD-‍1 therapy but who have allografted organs"
},
{
	"page":"ENAS5410_4.1.1.0",
	"text":"4.0.0.0 Summary of recommendations 4.1.0.0 Incidence and epidemiology 4.1.1.0 General aspects of irAEs irAEs generally occur within weeks to 3 months after initiation of ICPi treatment The role of tissue biopsy in diagnosis is not established but may be useful for higher grade (3–4) toxicities where there is diagnostic doubt and management would be altered by the outcome of the biopsy procedure"
},
{
	"page":"ENAS5410_4.1.2.0",
	"text":"4.1.2.0 Patient selection and baseline assessments Prior to starting treatment, patient&#039;s susceptibility to irAEs development should be assessed The work-‍up should include patient (and family) history, general physical condition, autoimmune diseases, baseline laboratory tests and radiological scans Patients who have a current, or a history of, autoimmune disease are at risk for worsening of their autoimmune disease while on ICPi treatment and those with previous ipilimumab-‍related irAEs are at risk of developing irAEs following anti- PD-1 treatment, and vice versa Patients should be informed of the potential AEs of immunotherapy before treatment initiation and should report directly to the treating physician or team Once irAEs have developed, prompt work-‍up and action are required Pneumocystis prophylaxis should be considered for patients receiving long-‍term (> 6 weeks) treatment with immunosuppressive drugs or infliximab The clinical outcome of patients on ICPi treatment is not affected by the use of immunosuppressive agents for the management of immune-‍related toxicities"
},
{
	"page":"ENAS5410_4.2.1.1",
	"text":"4.2.0.0 Immune-‍related toxicities 4.2.1.0 Immune-‍related skin toxicity 4.2.1.1 Overview The most common skin reactions are rash, pruritus and vitiligo Skin reactions can be classified into: Inflammatory skin disorders, immunobullous skin lesions, keratinocyte alteration and immune-reaction mediated by alteration of melanocytes"
},
{
	"page":"ENAS5410_4.2.1.2",
	"text":"4.2.1.2 Diagnosis and pathology Any other aetiology of the skin problem, such as infection, an effect of another drug or a skin condition linked to another systemic disease, should be ruled out The severity of the reaction should be evaluated by a careful and thorough physical examination of the skin, including the mucosal areas, and patient’s general health status A biological assessment, including blood cell count and liver and kidney tests, may be required to rule out dermatological emergencies: In severe cases, ICPi treatment should be permanently discontinued, the patient hospitalised and symptomatic treatment should be initiated immediately Severity of maculopapular rash should be classified according to the CTCAE version 4.0"
},
{
	"page":"ENAS5410_4.2.1.3",
	"text":"4.2.1.3 Management of rash For grade 1 skin AEs, ICPi treatment can be continued and symptomatic treatment with topical emollients, oral antihistamines and/‍or mild strength topical corticosteroids is recommended For grade 2 skin AEs, ICPi treatment can be continued but if the reaction has not resolved within a week, treatment should be interrupted until the skin AE has reverted to ≤ grade 1, and symptomatic treatment with topical emollients, oral antihistamines and medium-‍to-‍high-‍strength topical steroids is recommended Grade 3 skin reactions require immediate interruption of ICPi treatment until reactions are ≤ grade 1 and treatment with topical emollients, oral antihistamines and high-‍strength topical steroids, with consideration being given to systemic corticosteroids 0.5 to 1 mg/kg For grade 4 skin toxicity, ICPi treatment should be discontinued permanently and the patient admitted immediately for treatment under a dermatologist with IV (methyl)prednisolone 1–2 mg/kg, followed by tapering when toxicity resolves"
},
{
	"page":"ENAS5410_4.2.2.1",
	"text":"4.2.2 Immune-‍related endocrinopathies 4.2.2.1 Thyroid gland disorders Thyroid dysfunction events are detected by routine blood tests (TSH and FT4), which should be performed before every infusion or at least once a month (in the case of 2-‍weekly infusions) Substitution with thyroid hormone should be considered in asymptomatic patients with fatigue or other complaints that could be attributed to hypothyroidism In symptomatic patients, treatment with beta-‍blockers (propranolol or atenolol) should be initiated and treatment with ICPi treatment interrupted until symptoms resolve Rarely, carbimazole or steroids are required and treatment with ICPi should be interrupted until symptoms have resolved Long-‍term HRT is required in most patients"
},
{
	"page":"ENAS5410_4.2.2.2",
	"text":"4.2.2.2 Hypophysitis Headache and visual disturbances require immediate evaluation and differentiation between hypophysitis and other conditions A swollen or enlarged pituitary gland on brain MRI, together with simultaneous low blood levels of TSH, ACTH and/‍or FSH/‍LH, indicates hypophysitis as the most likely diagnosis Patients can present with hypothyroidism and/‍or hypocortisolism and complaints relating to low testosterone levels ICPi treatment should be interrupted in any grade 2 or higher reaction and HRT initiated immediately High-‍dose steroids are recommended for headaches and other neurological problems In most cases, ICPi treatment can be continued and long-‍term HRT is required"
},
{
	"page":"ENAS5410_4.2.2.3",
	"text":"4.2.2.3 Type 1 diabetes mellitus Blood glucose levels should be regularly monitored in patients treated with ICPi in order to detect the emergence of de novo DM Patients with Type 2 DM may develop ketoacidosis, which should be treated according to standard local guidelines The role of high-‍dose steroids in preventing total loss of pancreatic beta cells is unclear and is not recommended C-‍peptide and antibodies against GAD and islet cells can distinguish between Type 1 and Type 2 DM Recommencement of ICPi treatment can be considered once the patient has been regulated with insulin substitution"
},
{
	"page":"ENAS5410_4.2.3.1",
	"text":"4.2.3.0 Immune-‍related hepatotoxicity 4.2.3.1 Overview All patients should be assessed for signs and symptoms of hepatitis, with measurement of serum transaminase and bilirubin levels prior to every treatment cycle Disease-related, concomitant drug administration (including alcohol) and infectious causes should be ruled out but initiation of therapy should not be delayed while awaiting serological results Liver biopsy may be help in the differential diagnosis of more severe hepatitic reactions"
},
{
	"page":"ENAS5410_4.2.3.2",
	"text":"4.2.3.2 Management For moderate (grade 2) transaminase or total bilirubin elevation, ICPi therapy should be withheld and transaminases and bilirubin measured twice weekly For grade 2 elevation persisting for more than 1–2 weeks treatment with 1 mg/ kg/‍day (methyl)prednisolone or equivalent is recommended and, if symptoms improve, ICPi treatment may be resumed after corticosteroid tapering If symptoms do not improve, or worsen, the corticosteroid dose should be increased to 2 mg/‍kg/‍day (methyl)prednisolone or equivalent and ICPi therapy permanently discontinued For grade 3 or 4 transaminase or total bilirubin elevation, treatment with 1–2 mg/ kg/‍day (methyl)prednisolone or equivalent should be initiated and ICPi therapy permanently discontinued If there is no response to corticosteroids within 2–3 days, MMF (1,000 mg bid) should be added Options for third-‍line immunosuppressive therapy include ATG and tacrolimus"
},
{
	"page":"ENAS5410_4.2.4.1",
	"text":"4.2.4.0 Gastrointestinal toxicity 4.2.4.1 GI toxicity of anti-‍CTLA4 antibodies The most common presenting symptoms are diarrhoea, abdominal pain, hematochezia, weight loss, fever and vomiting, mouth ulcers, anal lesions and extra-‍intestinal manifestations The main biological abnormalities are anaemia, increased serum CRP and low serum albumin levels Bacterial enteropathogens and Clostridium difficile toxin content of stools and investigation of GI metastases can be used to rule out infection and cancer as causes of toxicity Flexible sigmoidoscopy can confirm the diagnosis of enterocolitis Upper GI symptoms (dysphagia and epigastric pain) and endoscopic lesions (oesophageal ulcerations, gastritis, duodenitis) have been reported Management Oral budesonide does not prevent ipilimumab-‍induced enterocolitis Patients with non-‍severe diarrhoea should be treated with antidiarrhoeals, fluid and electrolyte supplementation, if required, and anti-‍CTLA4 therapy can be continued For persistent grade 2 diarrhoea or severe diarrhoea (grade 3/4 diarrhoea, or grade 1/2 diarrhoea with alarm symptoms) anti-‍CTLA4 therapy discontinuation and initiation of systemic corticosteroids (1 to 2 mg/kg IV daily) is recommended Patients responding to IV corticosteroids within 3–5 days should be switched to the oral form and treatment should be tapered over 8–12 weeks; non-‍responders should be switched to infliximab 5 mg/kg (unless contraindicated) Patients developing a colonic perforation, with or without intra-‍abdominal abscess, should undergo emergency subtotal colectomy with ileostomy and sigmoidostomy Follow-‍up and long-‍term implications Treatment with corticosteroids or infliximab does not affect response and OS of patients treated with ipilimumab Reintroduction of anti-‍CTLA4 in patients who have previously experienced enterocolitis is associated with a high risk of relapse and should be discussed on an individual basis A severe AE with an anti-‍CTLA4 MoAb does not predict toxicity with an anti-‍PD-‍1 MoAb, and vice versa"
},
{
	"page":"ENAS5410_4.2.4.2",
	"text":"4.2.4.2 GI toxicity of anti-‍PD-‍1 antibodies Common symptoms include diarrhoea, nausea/vomiting and abdominal pain, with a median time to symptom onset of 3 months Endoscopic findings range from normal mucosa through mild erythema to severe inflammation and histological findings include lamina propria expansion, villus blunting, intra-‍epithelial neutrophils and increased crypt/‍gland apoptosis Recent studies have identified four different patterns of GI irAEs: Acute colitis, microscopic colitis, upper GI involvement and pseudo-‍obstruction"
},
{
	"page":"ENAS5410_4.2.4.3",
	"text":"4.2.4.3 Combined anti-‍CTLA4 and anti-‍PD-‍1 antibodies With combined anti-‍PD-‍1/anti-‍CTLA4 treatment, pancreatitis and small bowel enteritis, which may be visible on CT scan, require ICPi treatment discontinuation and initiation of immunosuppression"
},
{
	"page":"ENAS5410_4.2.5.1",
	"text":"4.2.5.0 Immune-‍related pneumonitis 4.2.5.1 Overview Any new respiratory symptom should prompt investigation to formally exclude lung toxicity and all patients presenting with pulmonary symptoms should be assessed by CT Radiological features include ground glass opacities, a cryptogenic organising pneumonia-‍like appearance and interstitial pneumonia pattern, as well as characteristics of hypersensitivity pneumonitis Lung biopsy is generally not required for patient management, unless there is doubt as to the aetiology of pulmonary infiltrates, when a VATS biopsy is the method of choice A bronchoscopy with BAL will support the identification of infections and is recommended in any symptomatic pneumonia"
},
{
	"page":"ENAS5410_4.2.5.2",
	"text":"4.2.5.2 Management Where immune-‍related pneumonitis is documented or suspected, immunosuppressive treatment should be started immediately Where it is not possibly to rule out infection using bronchoscopy, oral or IV broad-‍spectrum antibiotics should be administered in parallel to the immunosuppressive treatment for grade ≥ 3 pneumonitis For grade 1–2 pneumonitis, oral prednisone 1 mg/kg daily or equivalent with clinical assessment every 2–3 days initially is recommended, with additional radiological assessments for grade 2 pneumonitis, and possible ICPi treatment interruption Following recovery, steroids should be tapered over 4–6 weeks and ICPi treatment reintroduction delayed until the daily steroid dose is ≤ 10 mg of oral prednisone In grade 3–4 moderate-to-severe cases, hospitalisation, treatment with high- dose IV (methyl)prednisolone 2–4 mg/‍kg/‍day or equivalent and permanent discontinuation of ICPi treatment is recommended If there is no improvement after 2 days, additional immunosuppressive strategies, such as infliximab, MMF or cyclophosphamide, are recommended Steroids should be tapered slowly over at least 6 weeks to prevent recurrence following rechallenge"
},
{
	"page":"ENAS5410_4.2.6.1",
	"text":"4.2.6.0 Rare immune-‍related toxicities 4.2.6.1 Neurological toxicity A range of neurological events have been described with a time of onset from 6 to 13 weeks Progression of the underlying cancer, seizure activity, infection and metabolic derangement should be ruled out as causes and nerve conduction studies and lumbar puncture may assist in diagnosis Early consultation with a neurologist is advised For all but mild (grade 1) neurological symptoms, ICPi therapy should be withheld until the cause is determined Prednisolone 0.5–1 mg/kg should be considered for moderate symptoms High-‍dose oral prednisolone 1–2 mg/kg or IV equivalent is recommended for significant neurological toxicity Plasmapheresis or IVIg may be required for the treatment of myasthenia and GBS"
},
{
	"page":"ENAS5410_4.2.6.2",
	"text":"4.2.6.2 Cardiac toxicity Cardiac side effects have been reported to occur after treatment with ipilimumab, pembrolizumab and nivolumab and the incidence is higher with the combination of ipilimumab and nivolumab compared with nivolumab alone Early consultation with a cardiologist is recommended High-‍dose corticosteroids should be instituted rapidly if ICPi-‍induced cardiac side effects are suspected Escalation to other immunosuppressive drugs, such as infliximab, MMF and ATG, is recommended if symptoms do not respond promptly to steroids"
},
{
	"page":"ENAS5410_4.2.6.3",
	"text":"4.2.6.3 Rheumatological toxicity For mild or moderate symptoms, analgesia with paracetamol and/‍or NSAIDs is recommended; moderate symptoms may respond to prednisolone For severe symptoms, consultation with a rheumatologist and the use of high- dose corticosteroids and TNFα-‍blocking agents is recommended"
},
{
	"page":"ENAS5410_4.2.6.4",
	"text":"4.2.6.4 Renal toxicity Serum sodium, potassium, creatinine and urea prior to every ICPi treatment infusion is recommended Initial management involves stopping nephrotoxic drugs, ruling out infection and urinary tract obstruction and correcting hypovolaemia For significant renal dysfunction, ICPi treatment should be withheld and consideration given to the use of systemic (methyl)prednisolone 0.5–2 mg or equivalent In the event of severe renal dysfunction, a nephrologist should be consulted Renal biopsy may be used to clarify a difficult differential diagnosis Acute tubulo-‍interstitial nephritis with lymphocytic infiltration is a frequent biopsy finding"
},
{
	"page":"ENAS5410_4.2.6.5",
	"text":"4.2.6.5 Ocular toxicities Topical corticosteroids are recommended for episcleritis and anterior uveitis and systemic corticosteroids for severe ocular inflammation and orbital inflammation Intravitreal anti-‍VEGF treatment is recommended for choroidal neovascularisation"
},
{
	"page":"ENAS5410_4.2.6.6",
	"text":"4.2.6.6 Haematological toxicities The optimal treatment for immune-‍related haematological AEs is unknown and initiation of high-‍dose corticosteroids and other immunosuppressive drugs should be performed in close collaboration with a haematologist"
},
{
	"page":"ENAS5410_4.2.6.7",
	"text":"4.2.6.7 Allograft rejection Single-‍agent ipilimumab may be administered without causing rejection of cardiac, renal and liver allografts, but there is a risk of acute allograft rejection after anti-‍PD-‍1 therapy"
},
{
	"page":"ENAS5410_5.0.0.0",
	"text":"5-FU 5-‍fluorouracil 5-HT 5-‍hydroxytryptamine Ab antibiotic ABC Airway, Breathing and Circulation ABLC amphotericin B lipid complex AC anthracycline/‍cyclophosphamide ACCP American College of Chest Physicians ACE angiotensin converting enzyme AChR acetylcholine receptor ACTH adrenocorticotropic hormone ADL activities of daily living ADR adverse drug reaction AE adverse event AFSOS Association Francophone pour les Soins Oncologiques de Support ALT antibiotic lock therapy ANA antinuclear antibody ANC absolute neutrophil count ANCA anti-neutrophil cytoplasmic antibody aPTT activated partial thromboplastin time ARB angiotensin receptor blocker ARDS acute respiratory distress syndrome ASA 5-‍acetyl salicylic acid ASCO American Society of Clinical Oncology AST antimicrobial susceptibility testing ATB antibiotic ATG anti-thymocyte globulin BAL bronchoalveolar lavage BB beta-‍blocking agents BCoG bacitracin/‍clotrimazole/‍gentamicin bid twice daily bid M/W/F twice daily Monday/Wednesday/Friday BNP brain natriuretic peptides BP blood pressure BSA body surface area BSI blood stream infection C Candida Ca calcium CFU colony-‍forming unit CHF congestive heart failure ChT chemotherapy CINV chemotherapy-induced nausea and vomiting CLL chronic lymphocytic leukaemia CMV cytomegalovirus CNS coagulase-‍negative Staphylococcus CPGs Clinical Practice Guidelines CrCl creatinine clearance CRBSI catheter-‍related blood stream infection CRI catheter-‍related infection CRP C-‍reactive protein CRS cytokine-release syndrome CRT chemoradiotherapy CT computed tomography CTCAE Common Terminology Criteria of Adverse Events CTLA4 cytotoxic T lymphocyte-associated protein 4 CV cardiovascular CVA cerebrovascular accident CVAD central venous access device CVC central venous catheter CYP cytochrome P450 DADS diffuse alveolar damage syndrome DDx differential diagnosis DEX dexamethasone DM diabetes mellitus DMSO dimethyl sulfoxide DRESS drug rash with eosinophilia and systemic symptoms DT deceleration time of the early peak flow DTTP differential time to positivity DVH dose volume histogram DVT deep vein thrombosis DW dextrose water E Enterococcus E/A ratio ratio of early peak flow velocity to atrial peak flow velocity ECG electrocardiogram ECHO echocardiography EDTA ethylenediaminetetraacetate EGFR epidermal growth factor receptor EMA European Medicines Agency EMG electromyography EORTC European Organisation for Research and Treatment of Cancer ESBL Enterococcus Staphylococci Extended spectrum ß-‍lactamase ESMO European Society for Medical Oncology ESR erythrocyte sedimentation rate FBC full blood count FDA Food and Drug Administration FN febrile neutropaenia FSH follicle-stimulating hormone FT4 free thyroxine GAD glutamic acid decarboxylase GBM glomerular basement membrane GBS Guillain-Barré syndrome G-CSF granulocyte-‍colony stimulating factor GI gastrointestinal GM-‍CSF granulocyte-‍macrophage colony-‍stimulating factor GN glomerulonephritis GNB Gram-‍negative bacillus Hb haemoglobin HER2 human epidermal growth factor 2 HIV human immunodeficiency virus HNC head and neck cancer HRT hormone replacement therapy HSCT haematopoietic stem cell transplantation HSR hypersensitivity reaction HSV herpes simplex virus ICPi immune checkpoint inhibitor ID infectious diseases Ig immunoglobulin IgE immunoglobulin E IGF1 insulin-like growth factor 1 IgG immunoglobulin G IM intramuscular IMRT intensity-‍modulated radiotherapy INR international normalised ratio IR infusion reaction irAE immune-related adverse event ISOO International Society of Oral Oncology IV intravenous IVIg intravenous immunoglobulin IVRT isovolumic relaxation time K potassium KGF-1 keratinocyte growth factor-1 LCI lung clearance index LDH lactate dehydrogenase LFT liver function test LH luteinising hormone LKM liver kidney microsomal LLN lower limit of normal LMWH low molecular weight heparin LVD left ventricular dysfunction LVEF left ventricular ejection fraction M/C/S microscopy, culture and susceptibility MASCC Multinational Association of Supportive Care in Cancer MDR multi-‍drug resistant MEC moderately emetogenic chemotherapy MHD maximum heart distance mIAS mTOR inhibitor-‍associated stomatitis MIC minimum inhibitory concentration MMF mycophenolate mofetil MoAb monoclonal antibody MRA magnetic resonance angiogram MRI magnetic resonance imaging MRSA methicillin-resistant S. aureus mTOR mechanistic target of rapamycin MUGA multiple gated acquisition MuSK muscle-specific kinase Mx management n/a not available NaCl sodium chloride NASH non-alcoholic steatohepatitis NCCN National Comprehensive Cancer Network NCI-‍CTCAE National Cancer Institute-Common Terminology Criteria for Adverse Events NCS/EMG nerve conduction studies/electromyography NEG negative NK neurokinin NS normal saline NSAID non-‍steroidal anti-‍inflammatory drug NSCLC non-small-cell lung cancer NTCP normal tissue complication probability NYHA New York Heart Association od once daily ONS Oncology Nursing Society OS overall survival P pseudomonas PCR polymerase chain reaction PD-1 programmed death 1 PD-L1 programmed death ligand 1 PE pulmonary embolism PICC peripherally inserted central catheter PJP Pneumocystis jiroveci pneumonia POS positive PS performance status PTA polymyxin/tobramycin/amphotericin B PTV planning target volume QTc QT interval corrected for heart rate RA receptor agonist RINV radiotherapy-induced nausea and vomiting RT radiotherapy S Staphylococcus SC subcutaneous SCT stem cell transplantation SFNEP Société Francophone Nutrition Clinique et Métabolique SLA/LP soluble liver antigen/liver-pancreas antibody SMA smooth muscle autoantibody SOR Standards, Options and Recommendations methodology spp species SVC superior vena cava T3 triiodothyronine T4 thyroxine TB tuberculosis TBI total body irradiation TCLO transfer factor for carbon monoxide tds three times a day TEE trans-‍oesophageal echocardiogram TEN toxic epidermal necrolysis TFT thyroid function test TKI tyrosine kinase inhibitor TMP-‍SMZ trimethoprim–sulfamethoxazole TNFα tumour necrosis factor alpha TnI troponin tPA tissue plasminogen activator TPN total parenteral nutrition TPO thyroid peroxidase TSH thyroid-stimulating hormone U unit UEC urea, electrolytes, creatinine UFH unfractionated heparin ULN upper limit of normal UPCR urine protein to creatinine ratio US ultrasound VATS video-assisted thoracoscopic surgery VEGF vascular endothelial growth factor VEGFR vascular endothelial growth factor receptor VHNSS Vanderbilt Head and Neck Symptom Survey VitD vitamin D VKA vitamin K antagonist VTE venous thromboembolism WBC white blood cell WHO World Health Organization"
}
]